Human cytomegalovirus resistance to antiviral drugs: Diagnosis, monitoring and clinical impact

Journal of Antimicrobial Chemotherapy

Volumn 52, Issue 3, 2003, Pages 324-330

  Baldanti, Fausto ^a   Gerna, Giuseppe ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Antivirals; Drug resistance; HCMV

Indexed keywords

ANTIRETROVIRUS AGENT; CIDOFOVIR; FOSCARNET; GANCICLOVIR; VALGANCICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; CLINICAL FEATURE; CYTOMEGALOVIRUS INFECTION; DRUG DETERMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; GENOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MUTATIONAL ANALYSIS; NEPHROTOXICITY; ORGAN TRANSPLANTATION; PATIENT MONITORING; PHENOTYPE; REVIEW; VIRUS DETECTION; VIRUS STRAIN;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; PHENOTYPE;

EID: 0141518165     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg354     Document Type: Review

References (84)

1. Erice, A., Chou, S., Biron, K. K. et al. (1989). Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. New England Journal of Medicine 320, 289-93.
2. Jacobson, M. A., Drew, W. L., Feinberg, J. et al. (1991). Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. Journal of Infectious Diseases 163, 1348-51.
3. Stanat, S. C., Reardon, J. E., Erice, A. et al. (1991). Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir. Antimicrobial Agents and Chemotherapy 35, 2191-7.
4. Gerna, G., Baldanti, F., Zavattoni, M. et al. (1992). Monitoring of ganciclovir sensitivity of multiple human cytomegalovirus strains coinfecting blood of an AIDS patient by an immediate-early antigen plaque assay. Antiviral Research 19, 333-45.
5. Baldanti, F., Sarasini, A., Silini, E. et al. (1995). Four dually resistant human cytomegalovirus strains from AIDS patients: single mutations in UL97 and UL54 open reading frames are responsible for ganciclovir- and foscarnet-specific resistance, respectively. Scandinavian Journal of Infectious Diseases. Supplementum 99, 103-4.
6. Wolf, D. G., Smith, I. L., Lee, D. J. et al. (1995). Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma. Journal of Clinical Investigation 95, 257-63.
7. Chou, S., Guentzel, S., Michels, K. R. et al. (1995). Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. Journal of Infectious Diseases 172, 239-42.
8. Wolf, D. G., Lee, D. J. & Spector, S. A. (1995). Detection of human cytomegalovirus mutations associated with ganciclovir resistance in cerebrospinal fluid of AIDS patients with central nervous system disease. Antimicrobial Agents and Chemotherapy 39, 2552-4.
9. Sarasini, A., Baldanti, F., Furione, M. et al. (1995). Double resistance to ganciclovir and foscarnet of four human cytomegalovirus strains recovered from AIDS patients. Journal of Medical Virology 47, 237-44.
10. Smith, I. L., Shinkai, M., Freeman, W. R. et al. (1996). Polyradiculopathy associated with ganciclovir-resistant cytomegalovirus in an AIDS patient: phenotypic and genotypic characterization of sequential virus isolates. Journal of Infectious Diseases 173, 1481-4.
11. Boivin, G., Gilbert, C., Morissette, M. et al. (1997). A case of ganciclovir-resistant cytomegalovirus (CMV) retinitis in a patient with AIDS: longitudinal molecular analysis of the CMV viral load and viral mutations in blood compartments. AIDS 11, 867-73.
12. Baldanti, F., Simoncini, L., Talarico, C. L. et al. (1998). Emergence of a ganciclovir-resistant human cytomegalovirus strain with a new UL97 mutation in an AIDS patient. AIDS 12, 816-8.
13. Smith, I. L., Taskintuna, I., Rahhal, F. M. et al. (1998). Clinical failure of CMV retinitis with intravitreal cidofovir is associated with antiviral resistance. Archives of Ophthalmology 116, 178-85.
14. Gilbert, C., Handfield, J., Toma, E. et al. (1998). Emergence and prevalence of cytomegalovirus UL97 mutations associated with ganciclovir resistance in AIDS patients. AIDS 12, 125-9.
15. Jabs, D. A., Enger, C., Forman, M. et al. (1998). Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. The Cytomegalovirus Retinitis and Viral Resistance Study Group. Antimicrobial Agents and Chemotherapy 42, 2240-4.
16. Drew, W. L., Stempien, M. J., Andrews, J. et al. (1999). Cytomegalovirus (CMV) resistance in patients with CMV retinitis and AIDS treated with oral or intravenous ganciclovir. Journal of Infectious Diseases 179, 1352-5.
17. Abraham, B., Lastere, S., Reynes, J. et al. (1999). Ganciclovir resistance and UL97 gene mutations in cytomegalovirus blood isolates from patients with AIDS treated with ganciclovir. Journal of Clinical Virology 13, 141-8.
18. Jabs, D. A., Martin, B. K., Forman, M. S. et al. (2001). Mutations conferring ganciclovir resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. Journal of Infectious Diseases 183, 333-7.
19. Gerna, G., d'Arminio Monforte, A., Zavattoni, M. et al. (1998). Sharp drop in the prevalence of human cytomegalovirus leuko-DNAemia in HIV-infected patients following highly active antiretroviral therapy. AIDS 12, 118-20.
20. O'Sullivan, C. E., Drew, W. L., McMullen, D. J. et al. (1999). Decrease of cytomegalovirus replication in human immunodeficiency virus infected-patients after treatment with highly active antiretroviral therapy. Journal of Infectious Diseases 180, 847-9.
21. Deayton, J., Mocroft, A., Wilson, P. et al. (1999). Loss of cytomegalovirus (CMV) viraemia following highly active antiretroviral therapy in the absence of specific anti-CMV therapy. AIDS 13, 1203-6.
22. Soriano, V., Dona, C., Rodriguez-Rosado, R. et al. (2000). Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 14, 383-6.
23. Deayton, J. R., Wilson, P., Sabin, C. A. et al. (2000). Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy. AIDS 14, 1163-70.
24. Knox, K. K., Drobyski, W. R. & Carrigan, D. R. (1991). Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient. Lancet 337, 1292-3.
25. Lurain, N. S., Ammons, H. C., Kapell, K. S. et al. (1996). Molecular analysis of human cytomegalovirus strains from two lung transplant recipients with the same donor. Transplantation 62, 497-502.
26. Rosen, H. R., Benner, K. G., Flora, K. D. et al. (1997). Development of ganciclovir resistance during treatment of primary cytomegalovirus infection after liver transplantation. Transplantation 63, 476-8.
27. Alain, S., Honderlick, P., Grenet, D. et al. (1997). Failure of ganciclovir treatment associated with selection of a ganciclovir-resistant cytomegalovirus strain in a lung transplant recipient. Transplantation 63, 1533-6.
28. Baldanti, F., Simoncini, L., Sarasini, A. et al. (1998). Ganciclovir resistance as a result of oral ganciclovir in a heart transplant recipient with multiple human cytomegalovirus strains in blood. Transplantation 66, 324-9.
29. Kruger, R. M., Shannon, W. D., Arens, M. Q. et al. (1999). The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation. Transplantation 68, 1272-9.
30. Manso, J. V., Lambert, J. L., Ona, M. et al. (1999). Ganciclovir resistance in a heart transplant recipient infected by cytomegalovirus. International Journal of Cardiology 71, 97-8.
31. Mendez, J. C., Sia, I. G., Tau, K. R. et al. (1999). Novel mutation in the CMV UL97 gene associated with resistance to ganciclovir therapy. Transplantation 67, 755-7.
32. Bienvenu, B., Thervet, E., Bedrossian, J. et al. (2000). Development of cytomegalovirus resistance to ganciclovir after oral maintenance treatment in a renal transplant recipient. Transplantation 69, 182-4.
33. Limaye, A. P., Corey, L., Koelle, D. M. et al. (2000). Emergence of ganciclovir disease among recipients of solid-organ transplants. Lancet 356, 609-10.
34. Eckle, T., Prix, L., Jahn, G. et al. (2000). Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. Blood 96, 3286-9.
35. Eckle, T., Lang, P., Prix, L. et al. (2002). Rapid development of ganciclovir-resistant cytomegalovirus infection in children after allogeneic stem cell transplantation in the early phase of immune recovery. Bone Marrow Transplantation 30, 433-9.
36. Lurain, N. S., Bhorade, S. M., Pursell, K. J. et al. (2002). Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients. Journal of Infectious Diseases 186, 760-8.
37. Bhorade, S. M., Lurain, N. S., Jordan, A. et al. (2002). Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients. Journal of Heart and Lung Transplantation 21, 1274-82.
38. Sasaki, T., Okayama, A., Eizuru, Y. et al. (1997). Progressive retinitis-encephalitis due to ganciclovir-resistant cytomegalovirus associated with aplastic anemia. Internal Medicine 36, 375-9.
39. Wolf, D. G., Yaniv, I., Honigman, A. et al. (1998). Early emergence of ganciclovir-resistant human cytomegalovirus strains in children with primary combined immunodeficiency. Journal of Infectious Diseases 178, 535-8.
40. Gerna, G., Revello, M. G., Percivalle, E. et al. (1990). Quantification of human cytomegalovirus viremia by using monoclonal antibodies to different viral proteins. Journal of Clinical Microbiology 28, 2681-8.
41. Gerna, G., Revello, M. G., Percivalle, E. et al. (1992). Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for optimal quantitation of human cytomegalovirus antigenemia. Journal of Clinical Microbiology 30, 1232-7.
42. Percivalle, E., Revello, M. G., Vago, L. et al. (1993). Circulating endothelial giant cells permissive for human cytomegalovirus (HCMV) are detected in disseminated HCMV infections with organ involvement. Journal of Clinical Investigation 92, 663-70.
43. Gerna, G., Furione, M., Baldanti, F. et al. (1994). Comparative quantitation of human cytomegalovirus DNA in blood leukocytes and plasma of transplant and AIDS patients. Journal of Clinical Microbiology 32, 2709-17.
44. Spector, S. A., Wong, R., Hsia, K. et al. (1998). Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients. Journal of Clinical Investigation 116, 178-85.
45. Cope, A. V., Sabin, C., Burroughs, A. et al. (1997). Interrelationship among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factor for HCMV disease following liver transplantation. Journal of Infectious Diseases 176, 1484-90.
46. Chernoff, D. N., Miner, R. C., Hoo, B. S. et al. (1997). Quantification of cytomegalovirus DNA in peripheral blood leukocytes by a branched-DNA signal amplification assay. Journal of Clinical Microbiology 35, 2740-4.
47. Bitsch, A., Kirchner, H., Dupke, R. et al. (1993). Cytomegalovirus transcripts in peripheral blood leukocytes of actively infected transplant patients detected by reverse transcription-polymerase chain reaction. Journal of Infectious Diseases 163, 740-3.
48. Gerna, G., Baldanti, F., Middeldorp, J. M. et al. (1999). Clinical significance of expression of human cytomegalovirus pp67 late transcript in heart, lung, and bone marrow transplant recipients as determined by nucleic acid sequence-based amplification. Journal of Clinical Microbiology 37, 902-11.
49. Gerna, G., Baldanti, F., Lilleri, D. et al. (2000). Human cytomegalovirus immediate-early mRNA detection by nucleic acid sequence-based amplification as a new parameter for preemptive therapy in bone marrow transplant recipients. Journal of Clinical Microbiology 38, 1845-53.
50. Sullivan, V., Talarico, C. L., Stanat, S. C. et al. (1992). A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 358, 162-4.
51. Martin, D. F., Sierra-Madero, J., Walmsley, S. et al. (2002). A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. New England Journal of Medicine 346, 1119-26.
52. Sullivan, V., Biron, K. K., Talarico, C. et al. (1993). A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives. Antimicrobial Agents and Chemotherapy 37, 19-25.
53. Smith, I. L., Cherrington, J. M., Jiles, R. E. et al. (1997). High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. Journal of Infectious Diseases 176, 69-77.
54. Baldanti, F., Paolucci, S., Parisi, A. et al. (2002). Emergence of multiple drug-resistant human cytomegalovirus variants in two HIV-infected patients failing HAART. Clinical Infectious Diseases 34, 1146-9.
55. Gerna, G., Baldanti, F., Grossi, P. et al. (2001). Diagnosis and monitoring of human cytomegalovirus infection in transplant recipients. Reviews in Medical Microbiology 12, 155-75.
56. Chou, S., Marousek, G., Guentzel, S. et al. (1997). Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. Journal of Infectious Diseases 176, 786-9.
57. Chou, S., Marousek, G., Parenti, D. M. et al. (1998). Mutation in region III of the DNA polymerase gene conferring foscarnet resistance in cytomegalovirus isolates from 3 subjects receiving prolonged antiviral therapy. Journal of Infectious Diseases 178, 526-30.
58. Boivin, G., Gilbert, C., Morissette, M. et al. (1997). A case of ganciclovir-resistant cytomegalovirus (CMV) retinitis in a patient with AIDS: longitudinal molecular analysis of the CMV viral load and viral mutations in blood compartments. AIDS 11, 867-73.
59. Baldanti, F., Revello, M. G., Percivalle, E. et al. (1998). Use of the human cytomegalovirus (HCMV) antigenemia assay for diagnosis and monitoring of HCMV infections and detection of antiviral drug resistance in the immunocompromised. Journal of Clinical Virology 11, 51-60.
60. Bowen, E. F., Cherrington, J. M., Lamy, P. D. et al. (1999). Quantitative changes in cytomegalovirus DNAemia and genetic analysis of the UL97 and UL54 genes in AIDS patients receiving cidofovir following ganciclovir therapy. Journal of Medical Virology 58, 402-7.
61. Emery, V. C. & Griffiths, P. D. (2000). Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proceedings of the National Academy of Sciences, USA 97, 8039-44.
62. Lurain, N. S., Spafford, L. E. & Thompson, K. D. (1994). Mutation in the UL97 open reading frame of human cytomegalovirus strains resistant to ganciclovir. Journal of Virology 68, 4427-31.
63. Chou, S., Erice, A., Jordan, M. C. et al. (1995). Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. Journal of Infectious Diseases 171, 576-83.
64. Baldanti, F., Silini, E., Sarasini, A. et al. (1995). A three-nucleotide deletion in the UL97 open reading frame is responsible for the ganciclovir resistance of a human cytomegalovirus clinical isolate. Journal of Virology 69, 796-800.
65. Hanson, M. N., Preheim, L. C., Chou, S. et al. (1995). Novel mutation in the UL97 gene of a clinical cytomegalovirus strain conferring resistance to ganciclovir. Antimicrobial Agents and Chemotherapy 39, 1204-5.
66. Baldanti, F., Underwood, M. R., Stanat, S. C. et al. (1996). Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. Journal of Virology 70, 1390-5.
67. Baldanti, F., Underwood, M. R., Talarico, C. L. et al. (1998). The Cys607 → Tyr change in the UL97 phosphotransferase confers ganciclovir resistance to two human cytomegalovirus strains recovered from two immunocompromised patients. Antimicrobial Agents and Chemotherapy 42, 444-6.
68. Chou, S. & Meichsner, C. L. (2000). A nine-codon deletion mutation in the cytomegalovirus UL97 phosphotransferase gene confers resistance to ganciclovir. Antimicrobial Agents and Chemotherapy 44, 183-5.
69. Cihlar, T., Fuller, M. D., Mulato, A. S. et al. (1998). A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. Virology 248, 382-93.
70. Cihlar, T., Fuller, M. D. & Cherrington, J. M. (1998). Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. Journal of Virology 72, 5927-36.
71. Boivin, G., Gilbert, C., Gaudreau, A. et al. (2001). Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for HCMV retinitis. Journal of Infectious Diseases 184, 1598-601.
72. Lang, D. J. & Cheung, K. S. (1982). Effectiveness of acycloguanosine and trifluorothymidine as inhibitors of cytomegalovirus infection in vitro. American Journal of Medicine 73, 49-53.
73. Prix, L., Maierl, J., Jahn, G. et al. (1998). A simplified assay for screening of drug resistance of cell-associated cytomegalovirus strains. Journal of Clinical Virology 11, 29-37.
74. Gerna, G., Sarasini, A., Percivalle, E. et al. (1995). Rapid screening for resistance to ganciclovir and foscarnet of primary isolates of human cytomegalovirus from culture-positive blood samples. Journal of Clinical Microbiology 33, 738-41.
75. Pepin, J. M., Simon, F., Dussault, A. et al. (1992). Rapid determination of human cytomegalovirus susceptibility to ganciclovir directly from clinical specimen primocultures. Journal of Clinical Microbiology 30, 2917-20.
76. Tatarowicz, W. A., Lurain, N. S. & Thompson, K. D. (1991). In situ ELISA for the evaluation of antiviral compounds effective against human cytomegalovirus. Journal of Virological Methods 35, 207-15.
77. Stahle, E. L., Schloss, L., Sundqvist, V. A. et al. (1998). Solid phase ELISA for determination of the virus dose dependent sensitivity of human cytomegalovirus to antiviral drugs in vitro. Antiviral Research 40, 105-12.
78. Wingard, J. R., Stuart, R. K., Saral, R. et al. (1981). Activity of trifluorothymidine against cytomegalovirus. Antimicrobial Agents and Chemotherapy 20, 286-90.
79. Kesson, A. M., Zeng, F., Cunningham, A. L. et al. (1998). The use of flow cytometry to detect antiviral resistance in human cytomegalovirus. Journal of Virological Methods 71, 177-86.
80. Lipson, S. M., Soni, M., Biondo, F. X. et al. (1997). Antiviral susceptibility testing-flow cytometric analysis (AST-FCA) for the detection of cytomegalovirus drug resistance. Diagnostic Microbiology and Infectious Disease 28, 123-9.
81. Lurain, N. S., Thompson, K. D., Holmes, E. W. et al. (1992). Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents. Journal of Virology 66, 7146-52.
82. Alain, S., Mazeron, M. C., Pepin, J. M. et al. (1993). Rapid detection of cytomegalovirus strains resistant to ganciclovir through mutations within the gene UL97. Molecular and Cellular Probes 7, 487-95.
83. Bourgeois, C., Sixt, N., Bour, J. B. et al. (1997). Value of a ligase chain reaction assay for detection of ganciclovir resistance-related mutation 594 in UL97 gene of human cytomegalovirus. Journal of Virological Methods 67, 167-75.
84. Cha, T. A., Tom, E., Kemble, G. W. et al. (1996). Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. Journal of Virology 70, 78-83.